Related Experiment Video
Updated: Oct 24, 2025

In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
Increasing Participation of Women in Cardiovascular Trials: JACC Council Perspectives
Leslie Cho1, Amanda R Vest2, Michelle L O'Donoghue3
1Cleveland Clinic Heart, Vascular, Thoracic Institute, Cleveland, Ohio, USA.
Abstract:
Although some progress has been made in the last 3 decades to increase the number of women in clinical cardiology trials, review of recent cardiovascular literature demonstrates that women and underrepresented minority women are still underrepresented in most clinical cardiology trials. This is especially notable in trials of patients with coronary artery disease, heart failure with reduced ejection fraction, and arrhythmia studies, especially those involving devices and procedures. Despite the call from National Institutes of Health, Food and Drug Administration, Institute of Medicine, and various professional societies, the gap remains. This paper seeks to identify the barriers for low enrollment and retention from patient, clinician, research team, study design, and system perspectives, and offers recommendations to improve recruitment and retention in the current era.
Related Concept Videos
Coronary Artery Disease IV: Preventive Measures
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Coronary Artery Disease I: Introduction
Clinical Trials: Overview
Coronary Artery Disease III: Clinical Manifestations
Coronary Artery Disease V: Interprofessional Care

